Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia Dose-escalation Study to Access the Tolerability，Safety，Pharmacokinetics and Pharmacodynamics of Recombinant Human Thrombopoietin in the Patients With Different Degree of Liver Function Impairment

NCT03673215 is registered in ClinicalTrials.gov with Shenyang Sunshine Pharmaceutical Co., LTD. as lead sponsor.

NCT NCT03673215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03673215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia Dose-escalation Study to Access the Tolerability，Safety，Pharmacokinetics and Pharmacodynamics of Recombinant Human Thrombopoietin in the Patients With Different Degree of Liver Function Impairment
Lead sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase
Phase 1
Overall status
Unknown status
Start date
June 28, 2018
Completion date
December 31, 2020
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis